Bioprinting Simplified and Amplified

Why do MIT, Stanford, Johnson & Johnson, Genentech and other leading research labs rely on Allevi Bioprinters? Allevi helps their researchers achieve medical breakthroughs faster, more economically, and more efficiently thanks to its award-winning technology. 

Because of their usefulness in the lab and their promise to disrupt the field of personalized medicine, the demand for 3D Bioprinters is expected to grow exponentially in the years ahead. The global 3D bioprinting market was valued at USD 385.56 million in 2018. It is predicted to grow to $1.2B by 2024, just for printers and consumables.

Allevi Bioprinters are currently in use in 350 labs in 40 countries around the world. Leading scientists and researchers at the most prestigious institutions and respected healthcare companies are using them for everything from the development of sugar stents to join veins with fewer complications to systems for improved drug delivery. 

Bioprinting allows researchers to model disease, create custom 3D tissue, and study the body outside the body with a level of control and repeatability that was simply not possible as recently as 5 years ago. For pharmaceutical development, 3D Bioprinting offers a means of testing drugs faster, at a lower cost, and with greater biological relevance than animal testing or 2D in vitro studies.

3D Bioprinters use biocompatible materials (Bioinks) mixed with cells to print living tissue. By depositing Bioinks layer-by-layer, Bioprinters are able to create biological structures with complex geometries – just like you would find in the human body. This means as personalized and regenerative medicine continue to grow in popularity, Bioprinting gives doctors and researchers the tools to customize treatments and improve patient outcomes. Over 110,000 people in the US alone are on the organ transplant waiting list at any given time. There’s a large and growing need for an alternative to organ and tissue donation. Allevi Bioprinters and Bioinks are exciting new tools with the potential to eliminate the organ transplant waiting list.

There are three main reasons Allevi Bioprinters have been adopted by so many labs since their introduction in 2015. First, Allevi Bioprinters operate with the reliability and versatility none of its competitors can match. Researchers across disciplines use Allevi Bioprinters to create everything from brain tissue to bone scaffolds quickly with reproducible  results. The second advantage is their software which is intuitive and easy to use. This allows researchers to design and run custom experiments without wasting valuable time to learn arcane and complex coding. Third, and just as important, Allevi Bioprinters are capable of printing both Collagen and Matrigel Bioinks. These animal-based bioinks better replicate human tissue than the plant-based inks used by competitors.

Allevi is well positioned to take a leading share of the market growth thanks to significant partnerships with leading life-science companies in complementary categories that are already serving potential users. This compliments their robust patent portfolio and first-mover advantage in the market. Their user research is helping rapidly improve their products to better meet future market demands. And their board of directors is stacked with bioscience pioneers who’ve done it before including board chair, Frank McCaney, former CEO of several MedTech companies, Evangeline Gonzalez, former CMO at Life Technologies, Angelo Masciantonio, who founded three successful companies, and David Joseph, the founder of five life science companies that resulted in two IPOs and 2 M&As. Their scientific advisory board includes leading clinicians and academicians at Harvard, MIT, and Wake Forest.

For more information on Allevi and how their products will help transform medical research in the decades ahead, visit

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.